Fast disintegrating tablets market is anticipated to grow at a significant CAGR during the forecast period. The key factor that drives the market growth and rapid adoption of these tablets among the global population includes the improved patient compliance due to these tablets when compared to the conventional tablets and capsules. It is majorly due to the comparatively better taste of these orally disintegrating tablets than the traditional ones.
Another pivotal factor contributing substantially to the market growth comprises the ability of fast disintegrating tablets to bypass first-pass metabolism. This indicates that these tablets are effective in addressing the complexities related to drug concentration; thus it also sustains the bioavailability of self-administered drugs. This maintained bioavailability offered by such tablets specifically for protein and peptide-based therapeutics is a promising factor for market growth during the forecast period.
Some key players operating in the market include Teva, Merck, Mylan, Pfizer, Johnson and Johnson. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.
For instance, in December 2018, Biohaven Pharmaceutical Holding Co. Ltd. announced positive top-line results from a randomized, controlled Phase 3 clinical trial evaluating the efficacy and safety of its Zydis, which is an orally dissolving tablet / fast disintegrating formulation of Rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraines. Such successful clinical trials are anticipated to further provide a boost to the global market growth in the future years.
To Request a Sample of our Report on Fast Disintegrating Tablets Market: https://www.omrglobal.com/request-sample/fast-disintegrating-tablets-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Teva, Merck, Mylan, Pfizer, Johnson and Johnson among others.
Fast Disintegrating Tablets Market Report Segmentation
By Type
- Anti-Psychotics Drug
- Anti-Epileptics Drug
- Other
By Application
- CNS Diseases
- Gastrointestinal Diseases
- CVS Diseases
- Other
A full Report of Fast Disintegrating Tablets Market is Available @ https://www.omrglobal.com/industry-reports/fast-disintegrating-tablets-market
Fast Disintegrating Tablets Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/fast-disintegrating-tablets-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
